We reviewed bladder contraction evolution after sacral anterior root stimulator implantation in thirty patients operated on from 1984 to 1991. Two patients underwent a complete denervation with a reinnervation within a maximal time of seventeen months. One patient underwent a lesion, like a neuropraxia with a complete recovery at four months. Five patients have undergone a partial denervation with a recovery of miction by neurostimulation within the time of eighteen months. In three patients, bladder contraction disappeared for various reasons.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/nau.1930120514 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential for Misdiagnosis of Detrusor Underactivity Due to Urodynamic Voiding Position and Seating Characteristics.
Neurourol Urodyn
January 2025
Department of Obstetrics and Gynecology, Division of Urogynecology, Albany Medical Center, Albany, New York, USA.
Background: Detrusor underactivity (DUA) is a lower urinary tract (LUT) diagnosis that is diagnosed with multichannel urodynamic studies (UDS). The effect of voiding position and DUA detection is unclear.
Objectives: We investigated whether moving individuals from the UDS chair to their typical voiding position would more accurately assess detrusor function in cases of absent or nonrepresentative voiding.
Novel approach for noninvasive pelvic floor muscle strength measurement using extracorporeal surface perineal pressure measurement and machine learning modeling.
Digit Health
January 2025
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Jongno-gu, Seoul, Korea.
Objective: Accurate measurement of pelvic floor muscle (PFM) strength is crucial for the management of pelvic floor disorders. However, the current methods are invasive, uncomfortable, and lack standardization. This study aimed to introduce a novel noninvasive approach for precise PFM strength quantification by leveraging extracorporeal surface perineal pressure (ESPP) measurements and machine learning algorithms.
View Article and Find Full Text PDFThe Role of Anterior Vaginal Prolapse in Co-Existent Underactive Overactive Bladder Syndrome-A Retrospective Cohort Study.
J Clin Med
January 2025
Department of Obstetrics and Gynecology, ASST Monza, San Gerardo Hospital, University Milano-Bicocca, 20900 Monza, Italy.
CUOB (co-existent underactive overactive bladder) syndrome is a clinical entity that embraces storage and emptying symptoms, not strictly correlated with urodynamic findings. We assessed the differences between patients diagnosed with CUOB with/without cystocele. The study group was allocated from 2000 women who underwent urodynamic studies between 2008 and 2016.
View Article and Find Full Text PDFSenegalin-2: A Novel Hexadecapeptide from with Antibacterial and Muscle Relaxant Activities, and Its Derivative Senegalin-2BK as a Bradykinin Antagonist.
Biomolecules
December 2024
Jiangsu Clinical Innovation Center for Anorectal Diseases of T.C.M., Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, China.
The amphibian skin secretions are excellent sources of bioactive peptides, some of which and their derivatives exhibit multiple properties, including antibacterial and antagonism against bradykinin. A novel peptide Senegalin-2 was isolated from the skin secretions of frog. Senegalin-2 relaxed rat bladder smooth muscle (EC 17.
View Article and Find Full Text PDFDevelopment of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!